Many CFOs rely on contractually mandated discounts and rebates to gauge pharmacy plan health, but these metrics often obscure the true financial impact of high-cost medications. When utilization rates climb—driven by new indications and larger eligible patient populations—employers may secure better unit-price discounts while simultaneously seeing their total budget collapse under the weight of increased volume. A plan with 100 users spending $1 million annually might see that cost balloon to $1.26 million even after a 10% price reduction, simply because the user base expanded to 140 people.

Effective management requires shifting focus from percentage-based savings to proactive forecasting. Organizations should model costs for oncology, rare-disease therapies, and gene treatments separately from routine retail claims. By tracking persistence rates and new-to-therapy trends, companies can identify budget risks months before they manifest in fiscal reports. However, Pruitt warns against blunt denial tactics that trigger absenteeism and erode employee trust. Instead, sustainable strategies should integrate clinical guidelines with alternative sourcing and patient advocacy to ensure access remains intact without sacrificing financial stability.